LLY

981.8

-1.41%↓

JNJ

199.89

-0.85%↓

ABBV

222.81

-0.04%↓

UNH

323.54

+0.12%↑

AZN

89.56

-1.8%↓

LLY

981.8

-1.41%↓

JNJ

199.89

-0.85%↓

ABBV

222.81

-0.04%↓

UNH

323.54

+0.12%↑

AZN

89.56

-1.8%↓

LLY

981.8

-1.41%↓

JNJ

199.89

-0.85%↓

ABBV

222.81

-0.04%↓

UNH

323.54

+0.12%↑

AZN

89.56

-1.8%↓

LLY

981.8

-1.41%↓

JNJ

199.89

-0.85%↓

ABBV

222.81

-0.04%↓

UNH

323.54

+0.12%↑

AZN

89.56

-1.8%↓

LLY

981.8

-1.41%↓

JNJ

199.89

-0.85%↓

ABBV

222.81

-0.04%↓

UNH

323.54

+0.12%↑

AZN

89.56

-1.8%↓

Inicio・Lista de Acciones・Apellis Pharmaceuticals Inc

Apellis Pharmaceuticals Inc

Cerrado

SectorSalud

23.79 0.13

Comprar Vender

Resumen

Variación precio

24h

Actual

Mínimo

23.47

Máximo

24.13

Métricas clave
By Trading Economics
Ingresos	258M 216M
Ventas	280M 459M
P/B Media del Sector	58.889 80.03
BPA	1.67
Margen de beneficio	47.04
Empleados	705
EBITDA	258M 228M

Recomendaciones
By TipRanks
Recomendaciones	Comprar
Estimación a 12 meses	+60.32% upside

Estadísticas de Mercado
By TradingEconomics
Capitalización de Mercado	-1.1B 2.7B
Apertura anterior	23.66
Cierre anterior	23.79

Noticias sobre sentimiento de mercado

By Acuity

50%

166 / 374 Clasificación en Healthcare

Apellis Pharmaceuticals Inc Gráfico

El rendimiento pasado no es un indicador fiable de resultados futuros.

Noticias Relacionadas

9 dic 2025, 22:13 UTC

Ganancias

GE Vernova Raises Outlook, Doubles Dividend on Energy Market Momentum

9 dic 2025, 21:40 UTC

Ganancias

GameStop Sales Fall as Collectibles Remain Only Bright Spot

9 dic 2025, 18:51 UTC

Adquisiciones, fusiones, absorciones

Broadwood Partners Still Opposes Alcon's Higher Bid for Staar Surgical

9 dic 2025, 16:57 UTC

Principales Movimientos del Mercado

Clear Secure Rises on Medicare Identity Verification Contract

9 dic 2025, 23:46 UTC

Charlas de Mercado

Nikkei May Trade Rangebound Ahead of Fed Rate Decision -- Market Talk

9 dic 2025, 23:46 UTC

Adquisiciones, fusiones, absorciones

Legend Holdings Stake in Lenovo Now at 32.34%

9 dic 2025, 23:45 UTC

Adquisiciones, fusiones, absorciones

Legend Holdings: Remains Optimistic About Lenovo's Future Development Potential

9 dic 2025, 23:44 UTC

Adquisiciones, fusiones, absorciones

Legend Holdings: Purchased Lenovo Shares at Average Price of HK$9.7653/Share

9 dic 2025, 23:43 UTC

Adquisiciones, fusiones, absorciones

Legend Holdings: Acquired Lenovo Shares for Total Cash Consideration of HK$1.12B

9 dic 2025, 23:43 UTC

Adquisiciones, fusiones, absorciones

Legend Holdings: Acquired 115.17M Lenovo Shares From Open Market Between Nov. 21 and Dec. 9

9 dic 2025, 23:35 UTC

Charlas de Mercado

Gold Edges Higher Ahead of FOMC Decision -- Market Talk

9 dic 2025, 22:42 UTC

Ganancias

PepsiCo Wants to Boost Sales, Cut Costs. The Street Is Doubtful. -- Barrons.com

9 dic 2025, 21:50 UTC

Charlas de Mercado

Tech, Media & Telecom Roundup: Market Talk

9 dic 2025, 21:50 UTC

Charlas de Mercado

Basic Materials Roundup: Market Talk

9 dic 2025, 21:48 UTC

Charlas de Mercado

Hiring Confidence Slips in Canada Entering 2026 -- Market Talk

9 dic 2025, 21:36 UTC

Ganancias

Casey's General Stores: Fiscal 2026 EBITDA Is Expected to Increase 15% to 17% >CASY

9 dic 2025, 21:36 UTC

Ganancias

Casey's General Stores: Total Inside Gross Profit Increased 13.5% to $703.4M Compared to Prior Yr >CASY

9 dic 2025, 21:36 UTC

Ganancias

Casey's General Stores: Now Expects Inside Same-Store Sales to Increase 3% to 4% and an Inside Margin of 41% to 42% >CASY

9 dic 2025, 21:36 UTC

Ganancias

Casey's General Stores: Same-Store Fuel Gallons Up 0.8% Compared to Prior Yr With Fuel Margin of 41.6 Cents per Gallon, Total Fuel Gross Profit Increased 20.9% to $377.4M Compared to Prior Yr >CASY

9 dic 2025, 21:36 UTC

Ganancias

Casey's General Stores: Inside Same-Store Sales Increased 3.3% Compared to Prior Yr, and 7.5% on 2-Yr Stack Basis, With an Inside Margin of 42.4% >CASY

9 dic 2025, 20:28 UTC

Charlas de Mercado

Oil Futures Decline for Second Straight Session -- Market Talk

9 dic 2025, 20:27 UTC

Adquisiciones, fusiones, absorciones

Teck Resources: Merger of Equals With Anglo Amer Plc Approved by Both Classes of Teck Hldrs

9 dic 2025, 20:27 UTC

Adquisiciones, fusiones, absorciones

Teck Reports Voting Results From Special Meeting of Hldrs

9 dic 2025, 20:26 UTC

Charlas de Mercado

Adquisiciones, fusiones, absorciones

Moody's: Paramount's Warner Bid Makes Strategic Sense, With Risk -- Market Talk

9 dic 2025, 20:21 UTC

Charlas de Mercado

U.S. Natural Gas Extends Pullback on Shifting Weather Outlook -- Market Talk

9 dic 2025, 19:52 UTC

Ganancias

Correction to 58 S&P 500 Stocks Have Dividends Higher Than Treasuries. 10 Look Better Than Bonds. -- Barrons.com on Dec. 8

9 dic 2025, 19:17 UTC

Ganancias

Update: 58 S&P 500 Stocks Have Dividends Higher Than Treasuries. 10 Look Better Than Bonds. -- Barrons.com

9 dic 2025, 17:20 UTC

Charlas de Mercado

Basic Materials Roundup: Market Talk

9 dic 2025, 17:15 UTC

Charlas de Mercado

Global Commodities Roundup: Market Talk

9 dic 2025, 17:11 UTC

Ganancias

Nvidia Has Permission to Sell H200 Chips to China. Why It Might Not Matter Much for the Stock. -- Barrons.com

Comparación entre iguales

Cambio de precio

Apellis Pharmaceuticals Inc Esperado

Precio Objetivo

By TipRanks

60.32% repunte

Estimación a 12 meses

Media 38.14 USD 60.32%

Máximo 117.8 USD

Mínimo 18 USD

De acuerdo con 15 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Apellis Pharmaceuticals Inc Dist en los últimos 3 meses.

Consenso

By TipRanks

Comprar

15 ratings

Comprar

Mantener

Vender

De acuerdo con 15 analistas que ofrecen calificaciones bursátiles a para Apellis Pharmaceuticals Inc Dist en los últimos 3 meses.

Sentimiento

By Acuity

166 / 374 Clasificación en Salud

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

Acerca de Apellis Pharmaceuticals Inc

Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA). The company also develops APL-3007, a small interfering RNA, or siRNA, which is in a Phase 1 clinical trial, as well as an oral complement inhibitor that is in preclinical development. It has a collaboration and license agreement with Swedish Orphan Biovitrum AB (publ) for development and commercialization of pegcetacoplan; and a collaboration with Beam Therapeutics Inc. focused on the use of Beam's base editing technology to discover new treatments for complement-driven diseases. The company was incorporated in 2009 and is based in Waltham, Massachusetts.